Pinealon

Pinealon (also known as EDR peptide, amino acid sequence Glu-Asp-Arg) is a synthetic tripeptide, meaning it is built from three amino acids: glutamic acid, aspartic acid, and arginine. It targets the brain and the pineal gland in a tissue-specific way [1,3]. Developed by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, Pinealon belongs to the family of bioregulator peptides (cytomedines), which are thought to directly influence cellular gene expression [1,3].

As a synthetic peptide, Pinealon was derived from the natural bovine brain cortex extract Cortexin, whose neuroprotective properties are largely due to the Glu-Asp-Arg motif it contains [1]. While the related Khavinson peptide Epithalon primarily targets telomerase activity, preclinical research on Pinealon focuses on the targeted protection of nerve cells and neurological anti-aging processes.

How is Pinealon used? Dosage and forms of administration

In Russian clinical practice, Pinealon is primarily given orally as a capsule at 20 mg daily for 10-20 days, with 1-2 treatment courses per year [3,4]. This oral form is the original pharmaceutical version, and Pinealon was at times registered as a medication in Russia.

On the gray market, however, Pinealon is usually sold as a lyophilized powder for daily subcutaneous injection of 1-2 mg over 10-20 days. These dosages are based purely on unsubstantiated user practices from online forums, with no basis in clinical studies. Occasionally, intranasal administration is also discussed for direct uptake into the brain, but there is no clinical evidence for this either [3].

Outside of its historical use in Russia, there is no validated human dosage and no approval from the FDA or EMA. All intake protocols circulating on the gray market are pure extrapolations and have no evidence-based medical foundation.

Mixing Pinealon: Reconstitution and dosage calculation

For subcutaneous injection, lyophilized Pinealon powder (usually 10 mg or 20 mg per vial) is reconstituted with a solvent such as BAC water (bacteriostatic water with 0.9% benzyl alcohol). A detailed step-by-step guide for hygienic mixing and storage can be found in the guide to mixing and storing.

Here is a worked example for reconstituting a 20 mg vial of Pinealon:

This calculation example only documents the unsubstantiated user practice and is not a clinically validated dosage recommendation. After reconstitution with BAC water, the vial must be stored in the refrigerator at 2-8 °C and used within 20-30 days.

Effects and mechanism of action of Pinealon in the body

As an ultra-short tripeptide, Pinealon works by penetrating directly into the cell nucleus, where, according to the Khavinson group's hypothesis, it interacts with DNA and histones and specifically modulates gene expression [1,3]. Unlike larger peptides, Pinealon does not need membrane-bound receptors to trigger biological effects at the cellular level [1,3].

In preclinical cell culture and animal models, the following molecular effects of Pinealon have been demonstrated:

• Reduction of reactive oxygen species (ROS) to lower oxidative stress and cell damage [1]
• Decrease in necrotic cell death in nerve cells under cellular stress conditions [1]
• Activation of the ERK 1/2 signaling cascade to promote cell division and neuronal survival [1]
• Increase in antioxidant enzymes such as SOD2 and GPX1 [3]
• Modulation of serotonin synthesis through regulation of the tryptophan hydroxylase gene [2]
• Regulation of proapoptotic proteins such as caspase-3 and p53 to control programmed cell death [3]

In addition, a microarray gene analysis showed that Pinealon modulates the expression of 62 brain-specific genes that are central to neuronal survival, synaptic plasticity, and mitochondrial function [3].

Study situation and scientific research on Pinealon

The scientific evidence on Pinealon is mostly preclinical and is based almost exclusively on in vitro and animal models from Vladimir Khavinson's research group. The published studies mainly examine cellular protective mechanisms against oxidative stress as well as gene expression patterns:

The only clinical publication in humans is the Russian-language work by Umnov et al. (2013), which describes neuroprotective effects of peptide bioregulators across different age groups [4]. However, this is not a controlled double-blind study by Western standards, and the reported memory improvements in seniors are not supported by independent control group studies [3].

To date, there is no FDA/EMA approval and no Western clinical phase II/III studies on Pinealon. Since all the primary literature comes from a single research group, independent scientific replication of the results is still lacking.

Possible risks and side effects of Pinealon

So far, there are no systematic safety data for Pinealon from controlled clinical human studies. While in vitro and animal models have not shown acute toxicity, the limited data does not allow for a reliable risk assessment in humans.

Key safety aspects of Pinealon remain scientifically unresolved:

• Possible interactions with other medications and active substances
• Long-term effects and late effects of repeated treatment courses
• Safety profile during pregnancy, breastfeeding, and in people with pre-existing conditions of the nervous system
• Actual gastrointestinal bioavailability, as the peptide can be enzymatically broken down in the digestive tract when taken orally

Additionally, the postulated mechanism of direct epigenetic DNA interaction raises unresolved safety questions. The guide Protection when ordering explains independent criteria for checking unapproved gray market sources.

Pinealon compared to other Khavinson bioregulators

Pinealon is part of a structural family of synthetic bioregulator peptides developed by Khavinson, in which each specific amino acid sequence is directed at a defined target organ. The differentiation is based on the respective biological target tissue:

In user communities, Pinealon and Epithalon are often combined sequentially in 10-day cycles, although there is no clinical evidence of efficacy or safety for this approach. The peptide library offers a systematic comparison of other bioregulators.

Conclusion: Summary of the effects, evidence, and safety of Pinealon

Pinealon is an experimental tripeptide (Glu-Asp-Arg) that shows neuroprotective effects in preclinical models through direct nuclear gene modulation mechanisms. However, all efficacy data on reducing oxidative stress comes almost exclusively from a single research group (Khavinson) and has not been confirmed by independent studies.

In practice, Pinealon is not an approved medication in the EU or the US and has no validated human dosage for evidence-based therapies. Gray market dosages remain speculative, which is why a strict distinction between preclinical laboratory hypotheses and actual clinical evidence is necessary.